VANCOUVER, British Columbia, Dec. 12, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) is pleased to announce that it has received...
VANCOUVER, British Columbia, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) has granted incentive stock options under...
VANCOUVER, British Columbia, Aug. 27, 2024 (GLOBE NEWSWIRE) -- ANORTECH INC. (“AnorTech” or the “Company”) (TSX Venture Exchange “ANOR”; OTC “HUDRF”) is pleased to announce that it has completed...
Acquisition to Strengthen Transplant and Oncology Businesses CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq:...
CAMBRIDGE, Mass. and VANCOUVER, B.C., Nov. 7 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR; TSX: AOM) announced today the expiration of the waiting...
AnorMED Board Recommends Shareholders Accept Genzyme Offer LANGLEY, BC, Nov. 3 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or the "Company") (NASDAQ:ANOR; TSX:AOM) today released its...
VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ -- AnorMED Inc. (NASDAQ:ANOR; TSX:AOM) today announced that it has completed enrollment in the second pivotal Phase III clinical trial evaluating its...
Genzyme to Gain Late-Stage Transplantation Product Candidate VANCOUVER, BC, and CAMBRIDGE, MA, Oct. 17 /PRNewswire-FirstCall/ -- Genzyme Corporation (NASDAQ:GENZ) and AnorMED Inc. (Nasdaq: ANOR;...
Millennium has the right to match Genzyme's 'superior proposal' VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ -- AnorMED Inc. ("AnorMED" or "the Company") (NASDAQ:ANOR; TSX:AOM) announced that it...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.01 | 50 | 0.02 | 0.03 | 0.02 | 146510 | 0.02911251 | CS |
4 | 0.01 | 50 | 0.02 | 0.03 | 0.015 | 144295 | 0.02192212 | CS |
12 | 0.005 | 20 | 0.025 | 0.03 | 0.015 | 87651 | 0.02130581 | CS |
26 | 0.005 | 20 | 0.025 | 0.035 | 0.015 | 86448 | 0.02407235 | CS |
52 | 0 | 0 | 0.03 | 0.05 | 0.015 | 79433 | 0.02578013 | CS |
156 | 0 | 0 | 0.03 | 0.05 | 0.015 | 79433 | 0.02578013 | CS |
260 | 0 | 0 | 0.03 | 0.05 | 0.015 | 79433 | 0.02578013 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관